Sutro Biopharma Inc. (STRO)
STRO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$11.01
-17.09% on the day
Market cap
$182.6M
Micro cap
Revenue · 2025
$102.5M
+65.2% on 2024
Net income · 2025
-$191.0M
-186.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | STRO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001382101 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $102.5M |
| Net income | -$191.0M |
| Operating income | -$158.4M |
| Net margin | -186.4% |
| Operating margin | -154.5% |
| Revenue growth | +65.2% |
| Cash | $58.1M |
| Total assets | $173.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-04-01 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-08-12 |
| Latest current report | 8-K | 2026-08-12 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 624 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CGEN | Compugen Ltd. | $1.98 | -4.35% | $187.3M |
| IVVD | Invivyd Inc. | $0.6460 | -4.05% | $190.4M |
| DTIL | Precision BioSciences Inc. | $6.10 | -6.58% | $168.4M |
| CHRS | Coherus Oncology Inc. | $1.07 | +3.88% | $165.3M |
| IPHA | Innate Pharma S.A. ADS | $1.47 | -0.68% | $164.2M |
| ALEC | Alector Inc. | $1.87 | -10.10% | $208.8M |
| TARA | Protara Therapeutics Inc. | $2.62 | -5.42% | $154.8M |
| CMPX | Compass Therapeutics Inc. | $0.8570 | -8.59% | $154.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier